February 3, 2015
Europe and Australia are reassessing, recalling and reflecting on biosimilars and generic medications.
January 13, 2015
Last week, the United States inched closer to its first biosimilar approval. At a Wednesday meeting of the Food and Drug Administration’s Oncological Drugs Advisory Committee, panelists recommended approval for a filgrastim biosimilar.
January 6, 2015
The Alliance for Patient Access released today a new policy video offering a vital prescription for safe use of biosimilars: distinct naming conventions and comprehensive testing.
December 19, 2014
Patient access encountered a range of challenges in 2014 – some old, some new. Here’s a look back at the top seven issues that drove physicians to advocate for their patients this year.
September 23, 2014
By David Charles, M.D. and Mary Ann Chapman, Ph.D. If a prescription medication is approved for the treatment of a…
August 14, 2014
A group of specialty physician societies and members of AfPA’s National Physicians Biologics Working Group made a collective appeal to the Food and Drug Administration today for giving biosimilar follow-ons distinct names.
August 6, 2014
The FDA’s first biosimilar approval application has stirred high hopes among some members of the health care community – and heated debate among others.
July 25, 2014
An opponent to distinct names for biosimilar medications has petitioned the Food and Drug Administration with a new argument: Same old, same old works just fine.
June 17, 2014
Tracking and analyzing patients’ adverse reactions to medications – a process known as pharmacovigilance – is crucial to patient safety.
June 11, 2014
Patients worldwide need access to affordable biosimilars, the World Health Organizations’ World Health Assembly (WHA) says, but not at the expense of safety or science.
